• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ABEMACICLIB Drug Record

  • Summary
  • Interactions
  • Claims
  • ABEMACICLIB chembl:CHEMBL3301610 ApprovedAntineoplastic

    Alternate Names:

    VERZENIO
    ABEMACICLIB
    VERZENIOS
    LY-2835219
    HY-16297A
    LY2835219
    CS-1230
    LY 2835219
    chembl:CHEMBL3301610
    pubchem.compound:46220502
    chemidplus:1231929-97-7
    drugbank:12001

    Drug Info:

    Pharmaceutical Developer Eli Lilly
    Source Reported Drug Name(s) LY2835219
    Drug Class CDK/Rb Inhibitor
    (6 More Sources)

    Publications:

    von Witzleben et al., 2015, Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway., Cancer Res.
    Patnaik et al., 2016, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors., Cancer Discov
    Gelbert et al., 2014, Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine., Invest New Drugs
    Glover et al., 1992, Gastroenteritis outbreak at an industrial camp--British Columbia., Can. Commun. Dis. Rep.
    Sherr et al., 2016, Targeting CDK4 and CDK6: From Discovery to Therapy., Cancer Discov
    Xue Y et al., 2019, SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer., Nat Commun
    Xue Y et al., 2019, CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary., Nat Commun
  • ABEMACICLIB   CCND2

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • ABEMACICLIB   SMARCA4

    Interaction Score: 1.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30718506 30718512


    Sources:
    CIViC

  • ABEMACICLIB   CCND3

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • ABEMACICLIB   CDK6

    Interaction Score: 1.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Mechanism of Interaction Cyclin-dependent kinase 6 inhibitor
    Direct Interaction yes

    PMIDs:
    24919854


    Sources:
    ChemblInteractions CancerCommons TTD

  • ABEMACICLIB   CDKN2A

    Interaction Score: 1.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    26183925 27217383


    Sources:
    ClearityFoundationBiomarkers JAX-CKB OncoKB

  • ABEMACICLIB   CDK4

    Interaction Score: 0.91

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor
    Direct Interaction yes

    PMIDs:
    24919854


    Sources:
    ClearityFoundationBiomarkers ChemblInteractions CancerCommons TTD OncoKB

  • ABEMACICLIB   CCND1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • ABEMACICLIB   NRAS

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    27217383


    Sources:
    JAX-CKB

  • ABEMACICLIB   KRAS

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Evidence Type Actionable
    Approval Status Phase I

    PMIDs:
    27217383 1291017 26658964


    Sources:
    JAX-CKB CIViC

  • ABEMACICLIB   PGR

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ABEMACICLIB   ESR2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ABEMACICLIB   ERBB2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • ABEMACICLIB   ESR1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • ABEMACICLIB   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    27217383


    Sources:
    JAX-CKB

  • CancerCommons: LY2835219

    • Version: 25-July-2013

    Alternate Names:
    LY2835219 Drug Trade Name
    LY2835219 Drug Development Name

    Drug Info:
    Drug Class CDK/Rb Inhibitor
    Source Reported Drug Name(s) LY2835219
    Pharmaceutical Developer Eli Lilly

    Publications:

  • JAX-CKB: Abemaciclib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Patnaik et al., 2016, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors., Cancer Discov
    von Witzleben et al., 2015, Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway., Cancer Res.

  • CIViC: ABEMACICLIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Patnaik et al., 2016, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors., Cancer Discov
    Xue Y et al., 2019, CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary., Nat Commun
    Xue Y et al., 2019, SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer., Nat Commun

  • TTD: LY2835219

    • Version: 2020.06.01

    Alternate Names:
    D05SBO TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3301610

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3301610

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: abemaciclib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: LY2835219

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Abemaciclib

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Abemaciclib

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21